How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11864-010-0137-x.pdf
Reference41 articles.
1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71–96.
2. Aggarwal S: Targeted cancer therapies. Nat Rev Drug Discov 2010, 9:427–428.
3. Sandler A, Gray R, Perry MC, et al.: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542–2550.
4. Herbst RS, Sandler A, Treatment Outcomes by Tumor Histology in Eastern Cooperative Group (ECOG) Study E4599 of Bevacizumab (BV) with Paclitaxel/Carboplatin (PC) for Advanced Non-small Cell Lung Cancer (NSCLC): Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? J Thorac Oncol 2008, 3:S283.
5. Reck M, von Pawel J, Zatloukal P, et al.: Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009, 27:1227–1234.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. High CTHRC1 expression may be closely associated with angiogenesis and indicates poor prognosis in lung adenocarcinoma patients;Cancer Cell International;2019-11-29
2. Cost-effectiveness of precision medicine: a scoping review;International Journal of Public Health;2019-11-15
3. End-of-Life Health-Care Cost of Patients With Lung Cancer: A Retrospective Study;Health Services Research and Managerial Epidemiology;2019-01-01
4. Research on Current Curative Expenditure among Lung Cancer Patients Based on the “System of Health Accounts 2011”: Insights into Influencing Factors;Journal of Cancer;2019
5. Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC);Expert Review of Pharmacoeconomics & Outcomes Research;2018-06-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3